1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
2.01%
Cash & equivalents growing 2.01% while Drug Manufacturers - Specialty & Generic shows decline of -0.68%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
-31.62%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
-13.06%
Below half the Drug Manufacturers - Specialty & Generic median of 0.43% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-1.16%
Receivables growth is below half the Drug Manufacturers - Specialty & Generic median of 0.23% (much lower). Joel Greenblatt would investigate if this reflects stronger collection discipline.
-3.39%
Inventory growth less than half of Drug Manufacturers - Specialty & Generic median of 0.81%. Joel Greenblatt might see well-managed stock levels if revenue is fine.
84.07%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-1.68%
Below half the Drug Manufacturers - Specialty & Generic median of 0.45%. Jim Chanos would question if the company faces working capital strain.
-5.15%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.17%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-0.00%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-2.45%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.41%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-0.79%
Near Drug Manufacturers - Specialty & Generic median of -0.82%. Charlie Munger sees standard intangible additions in line with sector M&A or IP expansions.
216.11%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-40.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-2.90%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.93%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-2.72%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.25%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
2.04%
Payables growth below half of Drug Manufacturers - Specialty & Generic median of -1.11%. Joel Greenblatt sees more conservative payables management vs. peers.
-31.47%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-81.60%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-98.88%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-72.26%
Below half Drug Manufacturers - Specialty & Generic median of 1.21%. Joel Greenblatt sees fewer expansions than peers.
-16.68%
Below half Drug Manufacturers - Specialty & Generic median of 0.68%. Joel Greenblatt sees more conservative short-term leverage than peers.
-0.19%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-3.25%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
9.31%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-0.28%
Below half Drug Manufacturers - Specialty & Generic median of -0.77%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-7.19%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.03%. Jim Chanos suspects an alarming rise in overall leverage.
5.48%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.66%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.35%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-12.56%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-0.28%
Below half Drug Manufacturers - Specialty & Generic median of 0.06%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-2.72%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.25%. Joel Greenblatt sees more aggressive expansions than peers.
-7.30%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-9.02%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.20%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-13.12%
Above 1.5x Drug Manufacturers - Specialty & Generic median -1.61%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
